CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE ...

The FBI says counterfeit versions of the drugs can cause health issues. The FBI is warning the public about counterfeit compounded weight loss drugs on the market that claim to contain semaglutide ...

We all know that Ozempic, a GLP-1 receptor agonist medication, also called semaglutide, causes weight loss. On average, high-dose semaglutides, like in Wegovy, cause people to lose somewhere ...

Semaglutide is a drug used for weight loss. Oral tablets and injections are both effective ways to take semaglutide. Oral tablets do not require the use of needles, but you may need to take them ...

💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular events by 14% in people with type 2 diabetes and heart or kidney disease. ️ The ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Ozempic (semaglutide) is a prescription drug used for certain conditions in people with type 2 diabetes. Ozempic is given as an injection under your skin. Ozempic can be prescribed for adults with ...

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 (GLP-1) medication, marking the shortage as ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Female semaglutide users had more than a two-fold higher risk for hair loss than users of bupropion-naltrexone.